Daniel Pomposini, MD
Internal Medicine · Danville, VANPI 1992740294
Payments from drug & device makers
Across 435 payments — averaging $488.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$81K
- Esperion Therapeutics, Inc.$39K
- Novo Nordisk AS$36K
- Lexicon Pharmaceuticals, Inc.$34K
- Eisai Inc.$9K
- AstraZeneca$8K
- plus $5K from 25 others
What the payments were for
- Food & beverage$5,480100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 18 | $81,315 |
| Esperion Therapeutics, Inc. | 64 | $39,062 |
| Novo Nordisk AS | 26 | $35,556 |
| Lexicon Pharmaceuticals, Inc. | 1 | $33,944 |
| Eisai Inc. | 2 | $9,195 |
| AstraZeneca | 37 | $8,233 |
| Sanofi-aventis U.S. LLC | 14 | $1,112 |
| AbbVie(2 entities) | 63 | $834 |
| Novo Nordisk | 43 | $679 |
| Amgen | 30 | $519 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $374 |
| Lilly USA, LLC | 17 | $284 |
| Boehringer Ingelheim | 15 | $281 |
| Amarin Pharma, Inc. | 11 | $254 |
| Merck | 13 | $197 |
| Bayer | 10 | $152 |
| Pfizer | 6 | $136 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $85 |
| Arbor Pharmaceuticals, Inc. | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 4 | $57 |
| Biogen | 3 | $50 |
| Lundbeck LLC | 2 | $48 |
| Novartis | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Genentech USA, Inc. | 3 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Corcept Therapeutics | 1 | $21 |
| GSK | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$212,683 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $145,304 |
| TrulicityDulaglutide | 66 | $117,718 |
| FarxigaDapagliflozin Propanediol | 40 | $52,189 |
| OzempicSemaglutide | 33 | $41,161 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $28,591 |
| JanuviaSitagliptin Phosphate | 17 | $28,378 |
| KerendiaFinerenone | 11 | $19,776 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $19,323 |
| NexletolBempedoic Acid | 20 | $18,538 |
| SynthroidLevothyroxine Sodium | 132 | $15,691 |
| TradjentaLinagliptin | 11 | $13,125 |
| Ezetimibe | 317 | $7,901 |
| Atorvastatin Calcium | 701 | $5,923 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,805 |
| Rosuvastatin Calcium | 256 | $4,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $281 | $158,429137 claims |
| Lilly USA, LLCTrulicity | $284 | $117,71866 claims |
| AstraZenecaFarxiga | $8,233 | $52,18940 claims |
| Novo NordiskOzempic | $679 | $41,16133 claims |
| MerckJanuvia | $197 | $28,37817 claims |
| BayerKerendia | $152 | $19,77611 claims |
| Esperion Therapeutics, Inc.Nexletol | $39,062 | $18,53820 claims |
| AbbVieSynthroid | $834 | $15,691132 claims |
| GSKBreo Ellipta | $14 | $4,80512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Danville
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.